- Home
- IONS vs COLB Comparison
IONS vs COLB Comparison
Compare IONS & COLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- COLB
- Stock Information
- Founded
- IONS 1989
- COLB 1993
- Country
- IONS United States
- COLB United States
- Employees
- IONS N/A
- COLB N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- COLB Major Banks
- Sector
- IONS Health Care
- COLB Finance
- Exchange
- IONS Nasdaq
- COLB Nasdaq
- Market Cap
- IONS 6.8B
- COLB 7.8B
- IPO Year
- IONS 1991
- COLB N/A
- Fundamental
- Price
- IONS $70.41
- COLB $25.66
- Analyst Decision
- IONS Strong Buy
- COLB Hold
- Analyst Count
- IONS 20
- COLB 16
- Target Price
- IONS $75.55
- COLB $29.00
- AVG Volume (30 Days)
- IONS 2.1M
- COLB 5.4M
- Earning Date
- IONS 10-29-2025
- COLB 10-30-2025
- Dividend Yield
- IONS N/A
- COLB 5.64%
- EPS Growth
- IONS N/A
- COLB 10.98
- EPS
- IONS N/A
- COLB 2.52
- Revenue
- IONS $944,050,000.00
- COLB $1,871,957,000.00
- Revenue This Year
- IONS $24.02
- COLB $27.45
- Revenue Next Year
- IONS $4.06
- COLB $28.14
- P/E Ratio
- IONS N/A
- COLB $10.14
- Revenue Growth
- IONS 16.05
- COLB 1.23
- 52 Week Low
- IONS $23.95
- COLB $19.61
- 52 Week High
- IONS $74.42
- COLB $32.85
- Technical
- Relative Strength Index (RSI)
- IONS 63.48
- COLB 50.16
- Support Level
- IONS $70.47
- COLB $24.75
- Resistance Level
- IONS $74.42
- COLB $25.69
- Average True Range (ATR)
- IONS 1.84
- COLB 0.92
- MACD
- IONS -0.64
- COLB -0.03
- Stochastic Oscillator
- IONS 37.12
- COLB 59.13
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About COLB Columbia Banking System Inc.
Columbia Banking System Inc is a registered bank holding company whose wholly-owned banking subsidiary is Columbia State Bank. The company provides a full range of banking services to small and medium sized businesses, professionals, and individuals throughout Washington, Oregon, Idaho, and California. The company's subsidiary Columbia Trust Company is an Oregon trust company that provides agency, fiduciary, and other related trust services with offices in Washington, Oregon, and Idaho. The firm offers various products and services under Personal Banking, Business Banking, and Wealth Management divisions.